Newsom rejects bill capping insulin prices in California.
California Governor Vetoes Bill to Limit Insulin Costs
California Governor Gavin Newsom has vetoed a bill that aimed to cap the cost of insulin for diabetes patients in the state. The bill, Senate Bill (SB) 90, proposed a maximum out-of-pocket expense of $35 for a 30-day supply of insulin.
“Bringing down the cost of prescription drugs has always been a priority for me,” said Governor Newsom in a letter explaining his veto. However, he believes that California’s plan to produce its own affordable insulin would be a more cost-effective solution.
Related Story
- Bill Limiting Insulin Cost to $35 Passes California Senate - Published on 5/30/2023
According to Governor Newsom, the state-branded insulin, known as CalRx, would cost patients $30 for a 1,000-unit vial or $55 for five 300-unit vials. However, this insulin is not expected to be available until next year.
In response to the governor’s decision, Senator Scott Wiener called it a “missed opportunity.” He expressed concern that people are forced to choose between buying insulin and affording basic necessities like food.
“This veto is a missed opportunity to ensure people can afford their medicine,” Senator Wiener stated.
In March, Governor Newsom announced a partnership with generic drug maker Civica to produce affordable insulin. California has invested $50 million into the development, manufacture, and distribution of the medicine.
Civica plans to produce three types of insulin under the CalRx label, which will be interchangeable with popular name brands. The manufacturing plant for the insulin is currently under construction in Petersburg, Virginia.
The partnership between California and Civica aims to reduce and prevent drug shortages and price spikes.
Overall, while the bill to limit insulin costs in California has been vetoed, the state’s efforts to produce affordable insulin through its partnership with Civica offer hope for patients in the future.
Why is the issue of insulin affordability far from resolved in California, despite the veto of SB 90
Down the cost of healthcare and ensuring access to affordable medication for all Californians is a priority for me,” Governor Newsom said in his veto message. ”However, SB 90 creates new problems without addressing the cost drivers for insulin, or the need to hold pharmaceutical companies accountable for unjustified price increases.”
The high cost of insulin has been a significant issue for diabetes patients in California and across the country. According to the American Diabetes Association, more than 34 million Americans have diabetes, and about 7.4 million depend on insulin to manage their condition. The cost of insulin has tripled over the past decade, making it increasingly difficult for patients to afford this life-saving medication.
SB 90 aimed to provide relief to diabetes patients by limiting their out-of-pocket expenses for insulin. Under the bill, insurance companies would have had to cap the cost of a 30-day supply of insulin at $35, regardless of the dosage required by the patient. This would have been a significant step towards ensuring that diabetes patients could afford the medication they need to survive.
However, Governor Newsom vetoed the bill, citing concerns about its effectiveness and potential unintended consequences. The Governor acknowledged the need to address the high cost of insulin but argued that SB 90 did not go far enough in holding pharmaceutical companies accountable for their pricing practices.
In his veto message, Governor Newsom proposed alternative solutions to address the cost of insulin. He called for increased transparency in drug pricing, including requiring pharmaceutical companies to provide justification for price increases. The Governor also emphasized the importance of exploring options to lower drug prices through negotiation and competition.
Despite the veto, the issue of insulin affordability is far from resolved in California. Diabetes patients and advocacy groups continue to push for measures to address the high cost of this life-saving medication. They argue that without government intervention, many patients will be forced to bear the burden of escalating insulin costs and face dangerous health outcomes.
California has been a leader in healthcare reform, implementing policies to expand access to healthcare and reduce costs. However, the high cost of prescription drugs, including insulin, remains a significant challenge. To truly address this issue, it is crucial to tackle the root causes of rising drug prices, hold pharmaceutical companies accountable, and ensure that patients can access affordable medications.
The debate over insulin costs is not exclusive to California, as many other states and countries also face similar challenges. It highlights the urgent need for comprehensive and sustainable solutions to make essential medications affordable for all.
In conclusion, Governor Gavin Newsom’s veto of SB 90, a bill aimed at capping insulin costs for diabetes patients, has drawn criticism from advocates who believe it was a missed opportunity to provide relief to those struggling with the high cost of insulin. While the Governor acknowledged the need for action, he argued that the bill did not go far enough in addressing the root causes of high insulin prices. The veto brings renewed focus to the issue of insulin affordability and highlights the ongoing need for comprehensive measures to ensure that essential medications remain accessible and affordable for all who need them.
" Conservative News Daily does not always share or support the views and opinions expressed here; they are just those of the writer."
